Kavroulaki Dimitra, Konstantinidou Elena, Tsiogka Anastasia, Rallis Konstantinos, Mavrikakis Emmanuel
Ophthalmology, General Hospital of Athens G. Gennimatas, Athens, GRC.
Opthalmology, General Hospital of Athens G. Gennimatas, Athens, GRC.
Cureus. 2023 May 30;15(5):e39695. doi: 10.7759/cureus.39695. eCollection 2023 May.
To assess the clinical benefits obtained with transcutaneous low-power, high-frequency quantum molecular resonance (QMR) electrotherapy in a group of multifactorial dry eye patients.
Fifty-one patients (total of 102 eyes) with dry eye symptoms were enrolled in the study. Included clinical conditions were meibomian gland dysfunction, glaucoma, cataract surgery within the past six months, and autoimmune disease-related superficial punctuate keratitis. The QMR treatment was administered using the Rexon-Eye device (Resono Ophthalmic, Sandrigo, Italy) for four consecutive weeks, with one 20-minute treatment session per week. The measured ocular parameters included non-invasive tear break-up time (NIBUT), corneal interferometry, lower eyelid meibography, and tear meniscus height, all measured at baseline, at the end of treatment, and two months after the end of treatment. The Ocular Surface Disease Index (OSDI) questionnaire was gathered at the same time. The study has received approval from our institution's ethics committee.
At the end of treatment, interferometry, tear meniscus height, and OSDI score improved at a statistically significant level. No statistically significant change was observed in NIBUT or meibography. At two months after the end of treatment, all parameters showed a statistically significant improvement, namely NIBUT, meibography, interferometry, tear meniscus, and OSDI score. No adverse events or side effects were reported.
The QMR electrotherapy by the Rexon-Eye device shows statistically significant improvement of dry eye clinical signs and symptoms with a duration of at least two months.
评估经皮低功率、高频量子分子共振（QMR）电疗法对一组多因素干眼症患者的临床疗效。
51例（共102只眼）有干眼症状的患者纳入本研究。纳入的临床情况包括睑板腺功能障碍、青光眼、过去6个月内的白内障手术以及自身免疫性疾病相关的浅层点状角膜炎。使用Rexon-Eye设备（意大利桑德里戈的Resono Ophthalmic公司）进行QMR治疗，连续四周，每周进行一次20分钟的治疗。测量的眼部参数包括非侵入性泪膜破裂时间（NIBUT）、角膜干涉测量、下睑睑板腺造影和泪河高度，均在基线、治疗结束时以及治疗结束后两个月进行测量。同时收集眼表疾病指数（OSDI）问卷。本研究已获得我们机构伦理委员会的批准。
治疗结束时，干涉测量、泪河高度和OSDI评分有统计学意义的改善。NIBUT或睑板腺造影未见统计学意义的变化。治疗结束后两个月，所有参数均有统计学意义的改善，即NIBUT、睑板腺造影、干涉测量、泪河和OSDI评分。未报告不良事件或副作用。
Rexon-Eye设备的QMR电疗法显示干眼症的临床体征和症状有统计学意义的改善，持续时间至少为两个月。
